1
|
Charron-Ligez F, Désy D, Auclair MH. Paclitaxel-induced periarticular thenar eminence erythema with onycholysis: A case report. SAGE Open Med Case Rep 2023; 11:2050313X231213930. [PMID: 38022865 PMCID: PMC10666682 DOI: 10.1177/2050313x231213930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2023] [Accepted: 10/01/2023] [Indexed: 12/01/2023] Open
Abstract
Paclitaxel is a drug frequently used in the treatment of gynecological cancers. Its cutaneous side effects are fairly well documented. A subtype of hand-foot syndrome, periarticular erythema of the thenar eminences with onycholysis, is rarer. Here, we present a case of a woman treated with paclitaxel for recurrent ovarian cancer who developed periarticular thenar eminence erythema with onycholysis syndrome. Involvement presented as an erythematous rash on the top of the left hand progressing up the arm. A lesion was also present on the right lower limb and on the dorsal surface of the right foot with onycholysis. Edema was present in the fingers, hands, forearms, and feet. A punch biopsy and pathological analysis confirmed the diagnosis of periarticular thenar eminence erythema with onycholysis syndrome. Rapid identification and treatment with topical corticosteroids limited irreversible damage.
Collapse
Affiliation(s)
| | - Delphine Désy
- Department of Pathology and Cellular Biology, Université de Montréal, Montréal, QC, Canada
| | - Marie-Hélène Auclair
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada
| |
Collapse
|
2
|
Zelman B, Lee K, Reserva J, Speiser J. A paclitaxel-induced variant of hand-foot syndrome affecting dorsal surfaces. J Cutan Pathol 2021; 48:1320-1323. [PMID: 33938036 DOI: 10.1111/cup.14040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Revised: 04/24/2021] [Accepted: 04/27/2021] [Indexed: 11/30/2022]
Affiliation(s)
- Brandon Zelman
- Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois, USA
| | - Kristin Lee
- Department of Dermatology, Loyola University Medical Center, Maywood, Illinois, USA
| | - Jeave Reserva
- Department of Dermatology, Loyola University Medical Center, Maywood, Illinois, USA
| | - Jodi Speiser
- Department of Pathology and Laboratory Medicine, Loyola University Medical Center, Maywood, Illinois, USA
| |
Collapse
|
3
|
Abstract
Palmar-plantar erythrodysesthesia (PPE) is an uncommon adverse event with paclitaxel. We report a case of PPE due to paclitaxel to create awareness and review management strategies. A 61-year-old female with locally advanced lobular breast cancer was started on neoadjuvant chemotherapy with four cycles of dose-dense doxorubicin and cyclophosphamide. She completed these chemotherapy cycles uneventfully and was started on weekly paclitaxel (80mg/m2) with a gap of two weeks. After receiving the sixth dose of paclitaxel, the patient presented with erythema, swelling, and discomfort of her hands and feet, interfering with her quality of life due to difficulty in carrying out daily routine activities. The changes were acute, occurred within a few days after the sixth dose of paclitaxel, and were consistent with PPE grade 2. Paclitaxel was discontinued, and the patient was switched to docetaxel every three weeks for two cycles. She used emollients and moisturizing creams for her local symptoms, after stopping paclitaxel, erythema, swelling, and discomfort of her hands and feet resolved within two weeks. She did not have a recurrence of these symptoms with docetaxel. Paclitaxel can cause PPE. Its incidence in the literature might be underreported. Discontinuation of paclitaxel can reverse skin toxicity and improve patient’s quality of life.
Collapse
Affiliation(s)
- Ahsan Wahab
- Internal Medicine, Baptist Medical Center South, Montgomery, USA
| | - Maria Khakwani
- Internal Medicine, Lahore Medical and Dental College, Lahore, PAK
| | - Hamid Ehsan
- Internal Medicine, MedStar Union Memorial Hospital, Baltimore, USA
| | - Naresh Bellam
- Hematology and Oncology, Prattville Campus, Montgomery Cancer Center, Prattville, USA
| |
Collapse
|
4
|
Kewan T, Alomari M, Khazaaleh S, Covut F, Olayan M. Hand-foot Syndrome Secondary to Low-dose Docetaxel in a Breast Cancer Patient. Cureus 2019; 11:e4400. [PMID: 31245190 PMCID: PMC6559678 DOI: 10.7759/cureus.4400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Accepted: 04/04/2019] [Indexed: 11/05/2022] Open
Abstract
Docetaxel-induced hand-foot syndrome (HFS) at low doses is a very rare side effect that usually occurs in a dose-dependent manner. HFS can be managed with conservative measures and may need chemotherapy discontinuation. In this report we present a case of HFS in a breast cancer patient after one dose of docetaxel.
Collapse
Affiliation(s)
- Tariq Kewan
- Internal Medicine, Cleveland Clinic - Fairview Hospital, Cleveland, USA
| | | | | | - Fahrettin Covut
- Internal Medicine, Cleveland Clinic - Fairview Hospital, Cleveland, USA
| | - May Olayan
- Internal Medicine, Cleveland Clinic - Fairview Hospital, Cleveland, USA
| |
Collapse
|
5
|
Marks DH, Qureshi A, Friedman A. Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events. JAMA Dermatol 2018; 154:1465-1472. [DOI: 10.1001/jamadermatol.2018.3465] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Dustin H. Marks
- The George Washington University School of Medicine and Health Sciences, Washington, DC
| | - Azam Qureshi
- Department of Dermatology, The George Washington University Medical Faculty Associates, Washington, DC
| | - Adam Friedman
- The George Washington University School of Medicine and Health Sciences, Washington, DC
- Department of Dermatology, The George Washington University Medical Faculty Associates, Washington, DC
| |
Collapse
|
6
|
J Pelletier D, O'Donnell M, Stone MS, Liu V. Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 2018; 45:453-457. [PMID: 29484689 DOI: 10.1111/cup.13138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Revised: 02/19/2018] [Accepted: 02/22/2018] [Indexed: 11/30/2022]
Abstract
Patients treated with intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma often become refractory and experience recurrent disease, thus necessitating alternative intravesical treatment modalities if the patient is to be spared the morbidities associated with radical cystectomy. Intravesical treatment with taxane-based chemotherapy, such as docetaxel, has gained traction in urologic oncology, proving to be an effective salvage therapy in such patients. Systemic taxane-based chemotherapeutic regimens have long been used in several advanced malignancies, and their systemic side-effects and associated histologic correlates have been extensively documented. In contrast to adverse effects associated with systemic administration, intravesical taxane administration has thus far proven to be well-tolerated, with little to no systemic absorption. To our knowledge, features of taxane-induced systemic effects have not been reported in this setting. Herein, we report a case of a patient with recurrent urothelial carcinoma treated with intravesical docetaxel, along with primary cutaneous anaplastic large cell lymphoma, who developed characteristic dermatotoxic histologic findings associated with intravenous taxane administration. As such histopathologic findings often represent close mimickers of neoplastic and infectious etiologies, knowledge of the potential for systemic manifestations of taxane therapy in patients treated topically may prevent potentially costly diagnostic pitfalls.
Collapse
Affiliation(s)
- Daniel J Pelletier
- Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Michael O'Donnell
- Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Mary Seabury Stone
- Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.,Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| | - Vincent Liu
- Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.,Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
| |
Collapse
|
7
|
Abstract
Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.
Collapse
|
8
|
Verdelli A, Antiga E, Bonciani D, Bonciolini V, Volpi W, Maio E, Caproni M. Docetaxel-induced-like subacute cutaneous lupus erythematosus. Clin Exp Dermatol 2015; 41:318-9. [PMID: 26350359 DOI: 10.1111/ced.12756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/24/2015] [Indexed: 11/26/2022]
Affiliation(s)
- A Verdelli
- Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Viale Michelangiolo, 41, 50125, Florence, Italy.
| | - E Antiga
- Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Viale Michelangiolo, 41, 50125, Florence, Italy
| | - D Bonciani
- Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Viale Michelangiolo, 41, 50125, Florence, Italy
| | - V Bonciolini
- Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Viale Michelangiolo, 41, 50125, Florence, Italy
| | - W Volpi
- Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Viale Michelangiolo, 41, 50125, Florence, Italy
| | - E Maio
- Department of Surgery and Translational Medicine, Division of Pathological Anatomy, University of Florence
| | - M Caproni
- Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Viale Michelangiolo, 41, 50125, Florence, Italy
| |
Collapse
|
9
|
Dow EN, Piccolo J, Segal EM, Charlson JA. Drug induced periarticular thenar erythema with onycholysis related to nano-albumin bound paclitaxel therapy. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/j.ctrc.2015.09.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
10
|
Abstract
Hematopoietic stem cell transplantation continues to be the mainstay of treatment for many hematologic dyscrasias and malignancies, including acute leukemias, lymphomas, and aplastic anemia. There can be significant complications, however, and often these complications are manifested in the skin as an eruption. Common among these are acute and chronic graft-versus-host disease, erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis, eruption of lymphocyte recovery, staphylococcal scalded skin syndrome, morbiliform drug eruptions, infections, and toxic erythema of chemotherapy. These entities can show significant clinical and histopathologic overlap, yet accurate distinctions among them are critical to initiating appropriate clinical interventions. In this review, we will discuss the key clinical and histopathologic findings in each entity as well as appropriate differential diagnostic entities.
Collapse
|